Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Jiangxi Univ. of Chinese Medicine ASK1 compound 26e
- Development stage
- Preclinical
- Lead developer
- Jiangxi University of Traditional Chinese Medicine
- Modality
- Small Molecules
01
Overview
Jiangxi Univ. of Chinese Medicine ASK1 compound 26e: sourced facts only. name: "Here, we report the discovery of a dibromo substituted quinoxaline fragment containing 26e as an effective small-molecule inhibitor of ASK1, with an IC50 value of 30.17 nM." [PMID:39431736]; target: "Here, we report the discovery of a dibromo substituted quinoxaline fragment containing 26e as an effective small-molecule inhibitor of ASK1, with an IC50 value of 30.17 nM." [PMID:39431736]; developer: "Jiangxi Provincial Key Laboratory of TCM Female Reproductive Health and Related Diseases Research and Transformation, Jiangxi University of Chinese Medicine, Nanchang, PR China." [PMID:39431736]; modality: "Here, we report the discovery of a dibromo substituted quinoxaline fragment containing 26e as an effective small-molecule inhibitor of ASK1, with an IC50 value of 30.17 nM." [PMID:39431736]; stage: "Further biochemical analyses revealed that 26e could reduce the content of T-CHO, LDL, and TG in FFA-induced LO2 cells, and had the potential to treat non-alcoholic fatty disease." [PMID:39431736]
02
Targets
MAP3K5 (ASK1)
Beyond the preview
Go deeper on Jiangxi Univ. of Chinese Medicine ASK1 compound 26e.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Jiangxi Univ. of Chinese Medicine ASK1 compound 26e.